Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 11.3% – What’s Next?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s stock price rose 11.3% during trading on Friday . The stock traded as high as $0.70 and last traded at $0.63. Approximately 151,239,068 shares changed hands during mid-day trading, an increase of 431% from the average daily volume of 28,475,689 shares. The stock had previously closed at $0.57.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a report on Sunday, December 15th. They issued a “sell” rating on the stock.

Tonix Pharmaceuticals Price Performance

The business’s fifty day moving average price is $0.19 and its 200-day moving average price is $0.52. The company has a market capitalization of $114.85 million, a P/E ratio of -0.01 and a beta of 2.23. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. The firm had revenue of $2.82 million during the quarter, compared to analysts’ expectations of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. As a group, sell-side analysts predict that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.